On November 22, Lionco Pharmaceutical Group announced that the company recently received a regulatory letter from the Second Division of the Shanghai Stock Exchange's listed company management regarding the "information disclosure of Lionco Pharmaceutical Group's 2024 third quarter report."
灵康药业收上交所监管工作函：要求说明前三季度存量制剂业务大增具体原因等
Lionco Pharmaceutical Group received a regulatory letter from the Shanghai Stock Exchange: requiring an explanation for the significant increase in the stock formulation business during the first three quarters, among other details.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated